Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Elpiscience Completes $100 Million Series B Financing for Immunotherapies

publication date: Dec 27, 2019

Shanghai's Elpiscience Biopharma closed a $100 million Series B round to develop its portfolio of 12 novel immunotherapy candidates through pre-clinical and clinical testing. The round was led by Hyfinity Investments. Just two years old, Elpiscience bases its drug development on its understanding of tumor biology and immunology. The company says its candidates must have a differentiated biology and then show efficacy in a platform that tests the molecule's benefits in clinical settings. Two weeks ago, Elpiscience signed a $21.4 million collaboration with two China banks to build a GMP manufacturing facility in Suzhou. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital